COMMUNIQUÉS West-GlobeNewswire

Childhood cancer treatment success reaches 87%, says Medicana specialist
07/10/2026
Professor Tezer Kutluk points to six decades of progress and the growing role of personalised treatment, while warning that access to care still determines children’s chances ISTANBUL, Türkiye, Oct. 07, 2026 (GLOBE [...]
Dubai Sets the Stage for the Future of Healthcare with Next Generation Medicine 2026
07/10/2026
DUBAI, United Arab Emirates, Oct. 07, 2026 (GLOBE NEWSWIRE) -- As Dubai rapidly solidifies its position as a global epicentre for preventive care, healthcare innovation, and health span extension, the Next Generation [...]
MUVON Therapeutics Reports Positive 12-Month Phase 2 Follow-up Data Confirming Durable Efficacy of its First-in-Class Muscle Regeneration Therapy in Stress Urinary Incontinence
07/10/2026
Zurich, Switzerland, October 7, 2026 – MUVON Therapeutics AG, a clinical-stage biotechnology company, reports positive 12-month interim results from the Long-Term Follow-Up Study of the Phase 2 clinical trial SUISSE- [...]
ITM and Lumara Bio to Announce New Data for ¹⁷⁷Lu-edotreotide (ITM-11) and Ga-DPI-4452 at EANM 2026
07/10/2026
Data will be presented in two top-rated oral presentations Meet the Expert session offers insights into Actinium-225 production Garching / Munich, October 7 , 2026 — ITM Isotope Technologies Munich SE (ITM) , a leading [...]
Teladoc Health Expands Solo Connected Care Platform with AI-Powered Capabilities to Help Hospitals Scale Smarter Care Delivery
07/10/2026
New SoloVitals and SoloScribe capabilities bring contactless vitals and ambient documentation directly into clinical workflows NEW YORK, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader [...]
Une nouvelle étude révèle qu’une majorité de jeunes hommes passent un temps excessif sur les médias sociaux, ce qui peut avoir des répercussions importantes sur leur santé mentale
07/10/2026
VANCOUVER, Colombie-Britannique, 07 oct. 2026 (GLOBE NEWSWIRE) -- Une recherche récente révèle que plus de la moitié des jeunes hommes canadiens passent plus de trois heures par jour sur les médias sociaux, ce qui [...]
New study finds a majority of younger men spend an unhealthy amount of time on social media, significantly impacting their mental health
07/10/2026
VANCOUVER, British Columbia, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Latest research shows more than half of young Canadian men spend over 3 hours a day on social media which significantly increases their risk of poor mental [...]
SparkLabs Taiwan Announces Professor Shan-Qun Huang’s Planned Return to Taiwan to Support International Capital Cooperation and Financial Talent Development
07/10/2026
TAIPEI, Taiwan, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Following the completion of a recent phase of overseas investment research projects, Professor Shan-Chun Huang is planning to gradually shift the focus of his next stage [...]
Matchpoint Therapeutics Announces $150 Million Series B Financing to Advance Pipeline of First-In-Class Oral Small Molecules for Autoimmune and Inflammatory Diseases
07/10/2026
Financing co-led by Nextech Invest and Norwest, with participation from new and existing investors Proceeds to support clinical development of MPT-062, an oral first-in-class T cell modulator, to begin in 2027 WATERTOWN [...]
Cadrenal Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process to Maximize Value of its Orphan Thrombo-Inflammatory Therapeutics
07/10/2026
Pipeline has reached clinical and regulatory maturity following recent alignment with FDA on Phase 3 development pathway for CAD-1005 Cadrenal has received strong interest from potential strategic partners Cadrenal will [...]
BillionToOne’s Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds
07/10/2026
Head-to-head comparison shows 94% concordance with tumor-informed ctDNA testing, with the clinical ground-truth in all discordant cases supporting Northstar Response MENLO PARK, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE [...]
Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2
07/10/2026
NEW YORK, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will [...]
Atavistik Bio to Present at the Cure HHT 16th International Scientific Conference
07/10/2026
Updated preclinical data and clinical trial-in-progress poster from the Harmony-HHT Phase 1/2 trial support the ongoing development of ATV-1601, an investigational oral allosteric inhibitor that selectively targets AKT1 [...]
Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease
07/10/2026
– Data showed improvements in an objective measure of impaired eye movement associated with Parkinson’s disease, with a correlation between reductions in LRRK2 cerebrospinal fluid (CSF) biomarkers to these changes in [...]
Novartis advances multiple sclerosis innovation with late-breaking remibrutinib and broad portfolio data at MSToronto2026
07/10/2026
Late-breaking data from positive Phase III REMODEL-1/-2 trials will show efficacy and safety profile of remibrutinib in RMS Novartis to hold virtual investor event highlighting REMODEL data and remibrutinib in MS Phase [...]
VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy
07/10/2026
Consistent Use of New Approach Methodologies (NAMs) to Potentially Accelerate BiTAC® Oncology Pipeline and Significantly Reduce Animal Testing Needs ZURICH, SWITZERLAND, Oct. 07, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech [...]
Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia
07/10/2026
First patient enrolled in cohort combining bexobrutideg with venetoclax Initial cohort to focus on relapsed/refractory CLL, with potential expansion to first-line CLL Strategy includes evaluation of bexobrutideg given [...]
Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day
07/10/2026
Licaminlimab genotype-based precision medicine approach for TNFR1-mediated dry eye disease in PREDICT-1 registrational symptoms trial on track for topline readout around year-end ZUG, Switzerland, October 7, 2026 -- [...]
125,000 Orion Corporation A shares converted into B shares
07/10/2026
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 7 OCTOBER 2026 at 9.00 EEST 125,000 Orion Corporation A shares converted into B shares In accordance with [...]

Pages